Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

European Union support for the Lebanese Healthcare System reaches €173 million

18 December 2018 - The European Union has renewed its commitment to strengthen the Lebanese health care system and secure access to chronic medications, vaccines and essential medical commodities to the most vulnerable population in Lebanon. Through an additional contribution of 19 million Euro from the EU Regional Trust Fund in response to the Syrian crisis, UNICEF and WHO will be able to support to people in need living in Lebanon by ensuring provision of primary healthcare services and strengthening the health system.
 
The additional funding was announced today during a joint press conference headed by the Minister of Public Health, Ghassan Hasbani, EU Ambassador Christina Lassen, WHO representative Dr. Imane Shankiti, and UNICEF Representative, Tanya Chapuisat. The donation is part of a package of support of 173 million Euro which the European Union has invested in the health sector to strengthen the system and to help meet the basic health needs of both Lebanese citizens and Syrian refugees in a time of great pressure on service delivery and health infrastructure.
 
“We thank the commitment of the European Union and the support of the World Health Organization and UNICEF in strengthening the healthcare system to meet the needs of both Lebanese and Syrian refugees,” said Minister Hasbany.
 
EU Ambassador Lassen highlighted that "the projects we are launching today are part of a 173 million Euro health package that includes primary and secondary healthcare and aims at achieving quality, affordable and accessible health services for everyone in need in Lebanon".
 
“The generous support of the EU to the health system has sealed a long-standing partnership between the MOPH, WHO and UNICEF, and ensured that health services were of good quality, and that outbreaks and health risks are identified and acted upon early enough” said Imane Shankiti, WHO representative. “Reinforcing the health system capacity, along with filling critical health services with EU support ensured that no patient in need for health care was left behind”.
 
“The strong partnership we have with the EU, the ministry of Public Health and WHO has ensured that every child in Lebanon has access to quality vaccines to remain safe from outbreaks of preventable diseases,” said Tanya Chapuisat, UNICEF Representative to Lebanon. “Through EU funding we are able to save lives and strengthen systems to shape a better future for children”.
 
 
    5
ATC Name B/G Ingredients Dosage Form Price
G01AX OVUMIX G Metronidazole - 300mg, Miconazole - 100mg, Neomycin (sulfate) - 48.8mg, Gotu Kola - 15mg, Polymixin sulfate - 4.4mg Suppository 395,090 L.L
C10BA05 OTOREZA G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 908,438 L.L
C10BA05 OTOREZA 10/10 G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 454,219 L.L
C10BA05 OTOREZA 10MG/20MG G Atorvastatin - 20mg, Ezetimibe - 10mg Tablet, film coated 858,715 L.L
C10BA05 OTOREZA 10MG/40MG G Atorvastatin - 40mg, Ezetimibe - 10mg Tablet, film coated 1,144,954 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 10mg 10mg Tablet 966,287 L.L
C10AA05 ORVASTA G Atorvastatin - 10mg 10mg Tablet, film coated 834,526 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 20mg 20mg Tablet 1,091,712 L.L
C10AA05 ORVASTA G Atorvastatin - 20mg 20mg Tablet, film coated 920,532 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 40mg 40mg Tablet 1,405,275 L.L
C10AA05 ORVASTA G Atorvastatin - 40mg 40mg Tablet, film coated 1,170,487 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 10mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,067,011 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 10mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,067,011 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 20mg, Amlodipine (besylate) - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,037,446 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 5mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,067,011 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,067,011 L.L
C09DB02 OLMENOR COMBI G Olmesartan medoxomil - 20mg, Amlodipine - 5mg Tablet, film coated 679,984 L.L
C09DB02 OLMENOR COMBI G Olmesartan medoxomil - 40mg, Amlodipine - 5mg Tablet, film coated 772,709 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 25mg Tablet, film coated 653,107 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 653,107 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 25mg Tablet, film coated 628,918 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 628,918 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 710,893 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 10mg 10mg Tablet, film coated 526,786 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 888,280 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 20mg 20mg Tablet, film coated 667,890 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 920,532 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 40mg 40mg Tablet, film coated 721,643 L.L
C09AA01 ORBACE G Captopril - 25mg 25mg Tablet 522,179 L.L
C09AA01 ORBACE G Captopril - 50mg 50mg Tablet 949,649 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025